Advanced

Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

Ahrén, Bo LU (2014) In World journal of diabetes 5(1). p.40-51
Abstract
There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1... (More)
There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1 receptor agonist (liraglutide). These studies show improved glycemia in the presence of limited risk for hypoglycemia and weight gain with the combination of incretin therapy with insulin. This article reviews the background and clinical studies on this combination. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
World journal of diabetes
volume
5
issue
1
pages
40 - 51
external identifiers
  • PMID:24567800
ISSN
1948-9358
DOI
10.4239/wjd.v5.i1.40
language
English
LU publication?
yes
id
2e74b5fa-199f-4a6e-a221-85166c61102e (old id 4334016)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24567800?dopt=Abstract
date added to LUP
2014-03-05 19:13:12
date last changed
2016-09-30 05:53:52
@misc{2e74b5fa-199f-4a6e-a221-85166c61102e,
  abstract     = {There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1 receptor agonist (liraglutide). These studies show improved glycemia in the presence of limited risk for hypoglycemia and weight gain with the combination of incretin therapy with insulin. This article reviews the background and clinical studies on this combination.},
  author       = {Ahrén, Bo},
  issn         = {1948-9358},
  language     = {eng},
  number       = {1},
  pages        = {40--51},
  series       = {World journal of diabetes},
  title        = {Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.},
  url          = {http://dx.doi.org/10.4239/wjd.v5.i1.40},
  volume       = {5},
  year         = {2014},
}